Vtv Therapeutics Stock Performance
| VTVT Stock | USD 16.04 0.53 3.42% |
VTv Therapeutics has a performance score of 2 on a scale of 0 to 100. The entity has a beta of -0.51, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning VTv Therapeutics are expected to decrease at a much lower rate. During the bear market, VTv Therapeutics is likely to outperform the market. vTv Therapeutics right now has a risk of 4.17%. Please validate VTv Therapeutics treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to decide if VTv Therapeutics will be following its existing price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in vTv Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, VTv Therapeutics may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Actual Historical Performance (%)
One Day Return 2.75 | Five Day Return 14.25 | Year To Date Return 48.52 | Ten Year Return (96.32) | All Time Return (96.32) |
Last Split Factor 1:40 | Last Split Date 2023-11-21 |
1 | Discretionary transaction by Al-nahyan Tahnoon Bin Zayed S. of tradable shares of VTv Therapeutics subject to Rule 16b-3 | 09/13/2024 |
2 | FMR LLC Acquires New Stake in vTv Therapeutics Inc | 11/13/2024 |
3 | Acquisition by Sekhri Paul J of 1378 shares of VTv Therapeutics at 16.3528 subject to Rule 16b-3 | 11/15/2024 |
4 | Acquisition by Sekhri Paul J of 1844 shares of VTv Therapeutics at 16.9569 subject to Rule 16b-3 | 11/18/2024 |
5 | Insider Buying Paul Sekhri Acquires Shares of vTv Therapeutics Inc | 11/20/2024 |
| Begin Period Cash Flow | 12.1 M |
VTv |
VTv Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,538 in vTv Therapeutics on September 1, 2024 and sell it today you would earn a total of 66.00 from holding vTv Therapeutics or generate 4.29% return on investment over 90 days. vTv Therapeutics is currently generating 0.1514% in daily expected returns and assumes 4.1743% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than VTv, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
VTv Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for VTv Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as vTv Therapeutics, and traders can use it to determine the average amount a VTv Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0363
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VTVT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.17 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.15 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average VTv Therapeutics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of VTv Therapeutics by adding it to a well-diversified portfolio.
VTv Therapeutics Fundamentals Growth
VTv Stock prices reflect investors' perceptions of the future prospects and financial health of VTv Therapeutics, and VTv Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on VTv Stock performance.
| Return On Equity | -3.62 | ||||
| Return On Asset | -0.41 | ||||
| Operating Margin | (22.86) % | ||||
| Current Valuation | (841.89 K) | ||||
| Shares Outstanding | 2.61 M | ||||
| Price To Earning | (4.19) X | ||||
| Price To Book | 2.70 X | ||||
| Price To Sales | 40.52 X | ||||
| Revenue | 9 K | ||||
| Gross Profit | (9.93 M) | ||||
| EBITDA | (25.41 M) | ||||
| Net Income | (20.25 M) | ||||
| Cash And Equivalents | 17.95 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 529 K | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 3.12 X | ||||
| Book Value Per Share | (11.84) X | ||||
| Cash Flow From Operations | (19.08 M) | ||||
| Earnings Per Share | (4.37) X | ||||
| Market Capitalization | 40.52 M | ||||
| Total Asset | 11.02 M | ||||
| Retained Earnings | (281.04 M) | ||||
| Working Capital | 38 K | ||||
| Current Asset | 52.12 M | ||||
| Current Liabilities | 10.58 M | ||||
About VTv Therapeutics Performance
Assessing VTv Therapeutics' fundamental ratios provides investors with valuable insights into VTv Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the VTv Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 53.56 | 65.50 | |
| Return On Tangible Assets | (1.84) | (1.93) | |
| Return On Capital Employed | (63.91) | (60.72) | |
| Return On Assets | (1.84) | (1.93) | |
| Return On Equity | 0.82 | 0.47 |
Things to note about vTv Therapeutics performance evaluation
Checking the ongoing alerts about VTv Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for vTv Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| vTv Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 9 K. Net Loss for the year was (20.25 M) with loss before overhead, payroll, taxes, and interest of (9.93 M). | |
| vTv Therapeutics currently holds about 17.95 M in cash with (19.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22. | |
| vTv Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 39.0% of the company outstanding shares are owned by insiders | |
| Latest headline from gurufocus.com: Insider Buying Paul Sekhri Acquires Shares of vTv Therapeutics Inc |
- Analyzing VTv Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether VTv Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining VTv Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating VTv Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of VTv Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of VTv Therapeutics' stock. These opinions can provide insight into VTv Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for VTv Stock Analysis
When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.